- $797.40m
- $767.39m
- $407.32m
Ardelyx sues US health department over kidney disease drug
U.S. RESEARCH ROUNDUP-Ardelyx, Eli Lilly, Tesla
Brief: Ardelyx Chose Not To Apply To Include Xphozah In CMS End-Stage Renal Disease Prospective Payment System Transitional Drug Add-On Payment Adjustment
Ardelyx Inc reports results for the quarter ended in March - Earnings Summary
Brief: Ardelyx Appoints Industry Veteran Mike Kelliher As EVP, Corporate Development, Strategy
U.S. STOCKS ON THE MOVE-Hyatt Hotels, Morningstar Inc, SunPower Corp
U.S. STOCKS ON THE MOVE-Universal Insurance, Rocket Companies, Legend Biotech
U.S. STOCKS ON THE MOVE-Carvana, Plug Power, Live Nation
U.S. STOCKS ON THE MOVE-Nvidia, Intuitive Machines, Block Inc
Ardelyx falls on wider-than-expected Q4 loss
U.S. RESEARCH ROUNDUP-Biomarin Pharmaceutical, Intuit, Penumbra
Ardelyx Inc reports results for the quarter ended in December - Earnings Summary
Brief: Ardelyx Provides Update On 2024 Strategic Priorities
Brief: Adage Capital Ups Stake In Kenvue, Chevron, Caterpillar; Takes In GSK
Brief: Ardelyx Says Geoffrey Block Stepping Down From Board Of Directors
U.S. STOCKS ON THE MOVE-Paramount Global, Bumble, Booking Holdings
U.S. STOCKS ON THE MOVE-Constellation Energy, Bloomin' Brands, Air Lease
Ardelyx says Xphozah now available in the US; shares rise
Brief: Ardelyx Announces XPHOZAH Now Available in the United States